126 related articles for article (PubMed ID: 15606376)
1. Advances in the management of hereditary medullary thyroid cancer.
Machens A; Ukkat J; Brauckhoff M; Gimm O; Dralle H
J Intern Med; 2005 Jan; 257(1):50-9. PubMed ID: 15606376
[TBL] [Abstract][Full Text] [Related]
2. [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization].
Frank-Raue K; Heimbach C; Rondot S; Usadel KH; Meng W; Varma C; Fuchs-Hammoser R; Höppner W; Schulze E; Raue F
Dtsch Med Wochenschr; 2003 Sep; 128(39):1998-2002. PubMed ID: 14508694
[TBL] [Abstract][Full Text] [Related]
3. Current management of medullary thyroid cancer.
Sippel RS; Kunnimalaiyaan M; Chen H
Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
[TBL] [Abstract][Full Text] [Related]
4. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
5. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.
Machens A; Schneyer U; Holzhausen HJ; Raue F; Dralle H
Surgery; 2004 Nov; 136(5):1083-7. PubMed ID: 15523405
[TBL] [Abstract][Full Text] [Related]
6. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
Quayle FJ; Moley JF
J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.
Frilling A; Weber F; Tecklenborg C; Broelsch CE
Langenbecks Arch Surg; 2003 Mar; 388(1):17-26. PubMed ID: 12690476
[TBL] [Abstract][Full Text] [Related]
9. Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities.
Machens A; Lorenz K; Dralle H
J Intern Med; 2009 Jul; 266(1):114-25. PubMed ID: 19522830
[TBL] [Abstract][Full Text] [Related]
10. The surgical management of medullary thyroid cancer.
Dackiw AP
Otolaryngol Clin North Am; 2010 Apr; 43(2):365-74, ix. PubMed ID: 20510719
[TBL] [Abstract][Full Text] [Related]
11. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of multiple endocrine neoplasia Type 2.
Bugalho MJ; Domingues R; Sobrinho L
Expert Rev Mol Diagn; 2003 Nov; 3(6):769-79. PubMed ID: 14628904
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.
Machens A; Dralle H
World J Surg; 2007 May; 31(5):957-68. PubMed ID: 17453286
[TBL] [Abstract][Full Text] [Related]
16. Medullary thyroid carcinoma: surgical treatment advances.
Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
[TBL] [Abstract][Full Text] [Related]
17. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
18. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
19. From genes to decisions: evolving views of genotype-based management in MEN 2.
Mulligan LM
Cancer Treat Res; 2004; 122():417-28. PubMed ID: 16209059
[TBL] [Abstract][Full Text] [Related]
20. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy.
Sakorafas GH; Friess H; Peros G
Endocr Relat Cancer; 2008 Dec; 15(4):871-84. PubMed ID: 19015274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
